Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Feb 25 (Reuters) – Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal ​worth up to $2.1 billion ‌to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesday.

Under the partnership, the privately held company ‌will ​license some of its ⁠oral drug-delivery technology, ⁠while Novo Nordisk will take charge of global development and commercialization.

Here are some details:

(Reporting by Kamal Choudhury in Bengaluru; Editing by ​Leroy Leo)